PMID- 20047480
OWN - NLM
STAT- MEDLINE
DCOM- 20100312
LR  - 20240315
IS  - 1537-6591 (Electronic)
IS  - 1058-4838 (Print)
IS  - 1058-4838 (Linking)
VI  - 50
IP  - 3
DP  - 2010 Feb 1
TI  - Clinical practice guidelines for the management of cryptococcal disease: 2010 
      update by the infectious diseases society of america.
PG  - 291-322
LID - 10.1086/649858 [doi]
AB  - Cryptococcosis is a global invasive mycosis associated with significant morbidity 
      and mortality. These guidelines for its management have been built on the 
      previous Infectious Diseases Society of America guidelines from 2000 and include 
      new sections. There is a discussion of the management of cryptococcal 
      meningoencephalitis in 3 risk groups: (1) human immunodeficiency virus 
      (HIV)-infected individuals, (2) organ transplant recipients, and (3) 
      non-HIV-infected and nontransplant hosts. There are specific recommendations for 
      other unique risk populations, such as children, pregnant women, persons in 
      resource-limited environments, and those with Cryptococcus gattii infection. 
      Recommendations for management also include other sites of infection, including 
      strategies for pulmonary cryptococcosis. Emphasis has been placed on potential 
      complications in management of cryptococcal infection, including increased 
      intracranial pressure, immune reconstitution inflammatory syndrome (IRIS), drug 
      resistance, and cryptococcomas. Three key management principles have been 
      articulated: (1) induction therapy for meningoencephalitis using fungicidal 
      regimens, such as a polyene and flucytosine, followed by suppressive regimens 
      using fluconazole; (2) importance of early recognition and treatment of increased 
      intracranial pressure and/or IRIS; and (3) the use of lipid formulations of 
      amphotericin B regimens in patients with renal impairment. Cryptococcosis remains 
      a challenging management issue, with little new drug development or recent 
      definitive studies. However, if the diagnosis is made early, if clinicians adhere 
      to the basic principles of these guidelines, and if the underlying disease is 
      controlled, then cryptococcosis can be managed successfully in the vast majority 
      of patients.
FAU - Perfect, John R
AU  - Perfect JR
AD  - Division of Infectious Diseases, Duke University Medical Center, Durham, North 
      Carolina 27710, USA. perfe001@mc.duke.edu
FAU - Dismukes, William E
AU  - Dismukes WE
FAU - Dromer, Francoise
AU  - Dromer F
FAU - Goldman, David L
AU  - Goldman DL
FAU - Graybill, John R
AU  - Graybill JR
FAU - Hamill, Richard J
AU  - Hamill RJ
FAU - Harrison, Thomas S
AU  - Harrison TS
FAU - Larsen, Robert A
AU  - Larsen RA
FAU - Lortholary, Olivier
AU  - Lortholary O
FAU - Nguyen, Minh-Hong
AU  - Nguyen MH
FAU - Pappas, Peter G
AU  - Pappas PG
FAU - Powderly, William G
AU  - Powderly WG
FAU - Singh, Nina
AU  - Singh N
FAU - Sobel, Jack D
AU  - Sobel JD
FAU - Sorrell, Tania C
AU  - Sorrell TC
LA  - eng
GR  - R01 AI073896/AI/NIAID NIH HHS/United States
GR  - AI73896/AI/NIAID NIH HHS/United States
PT  - Journal Article
PT  - Practice Guideline
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Clin Infect Dis
JT  - Clinical infectious diseases : an official publication of the Infectious Diseases 
      Society of America
JID - 9203213
RN  - 0 (Antifungal Agents)
SB  - IM
CIN - Ann Emerg Med. 2011 Jan;57(1):62-3. PMID: 21183085
MH  - Antifungal Agents/therapeutic use
MH  - Case Management/*standards
MH  - Child
MH  - Child, Preschool
MH  - Cryptococcosis/complications/*diagnosis/*therapy
MH  - Female
MH  - Humans
MH  - Intracranial Hypertension/surgery
MH  - Pregnancy
MH  - United States
PMC - PMC5826644
MID - NIHMS942528
COIS- Potential conflicts of interest. J.R.G. has served as a research consultant for 
      Schering-Plough. P.G.P. has received grant support from Schering-Plough, Pfizer, 
      Merck, and Astellas; has served as an ad hoc consultant to Pfizer; and has served 
      as a speaker to Pfizer and Astellas. J.R.P. has received grant support from 
      Merck, Astellas, Pfizer, Schering-Plough, and Enzon; has received honoraria from 
      Merck, Astellas, Pfizer, Schering-Plough, and Enzon; and has served as a 
      consultant to Merck, Astellas, Pfizer, Schering-Plough, and Enzon. T.C.S. has 
      received grant support from Pfizer, Merck, and Gilead and has served on advisory 
      boards for Pfizer, Merck, Gilead, and Schering-Plough. O.L. serves on speaker 
      bureaus for Merck, Schering-Plough, Pfizer, and Gilead Sciences. All other 
      authors: no conflicts.
EDAT- 2010/01/06 06:00
MHDA- 2010/03/13 06:00
PMCR- 2018/02/26
CRDT- 2010/01/06 06:00
PHST- 2010/01/06 06:00 [entrez]
PHST- 2010/01/06 06:00 [pubmed]
PHST- 2010/03/13 06:00 [medline]
PHST- 2018/02/26 00:00 [pmc-release]
AID - 10.1086/649858 [doi]
PST - ppublish
SO  - Clin Infect Dis. 2010 Feb 1;50(3):291-322. doi: 10.1086/649858.